A new brand of painkiller called Purdue’s “Purdue Acupuncture & Migraine Medicine” will help ease the constipation-related pain of many Americans, a Purdue executive says.
The painkiller will be available as an over-the-counter pill in pharmacies starting Monday, according to Purdue Chief Medical Officer Dr. David Kohn, and it will be marketed as a “non-toxic, effective, and non-irritating medication that can be taken by people with constipation and pain.”
Painkiller maker Purdue also plans to release a “new strain of pain reliever” in 2017 that it expects will be more potent and potentially offer a faster response, according a Purdue press release.
The drugmaker says its new “Pain Relief” drug is a “high-potency, non-toxin opioid analgesic that has been proven to reduce pain in patients with chronic pain and in individuals with mild to moderate to severe constipation, which can result in constipation recurrently.”
Purdue’s new Pain Relief is an “unrivaled non-invasive, pain-relieving alternative” to the existing painkillers that are available over-counter.
It is also the first time that a painkiller maker has been so proactive about treating constipation in an FDA-approved medication, according Purdue’s press release, which says the painkiller’s potency “will be proven clinically” and has a “minimal risk of adverse events.”
Predictably, constipation is one of the most common complaints among Americans.
According to a 2016 survey by the American Academy of Pain Medicine, about 1 in 10 adults with chronic constipation have a painful or constricting constipation.
More:Purdue has a patent on its Acupuncture&Migraine Medicine drug, but it has yet to release any details about its new formulation.
The company does not disclose how much of its drug is used for constipation management.
The patent does not require any further proof that the drug has a specific therapeutic effect, Kohn said in the release.
However, a company spokeswoman said in an email that the company is “proud to have developed an innovative drug that will help patients with constriction of the abdomen.”
“Our Pain Relief product is designed to reduce constipation’s impact and may reduce constrictions in the short term, but will not be able to reverse constipation altogether,” she said.
Purdue did not respond to a request for comment.
The new painkillers are part of Purdue’s effort to broaden its offerings to address the rising number of chronic constrictive conditions.
A 2015 study by the Pain Management Foundation of the United States and the United Kingdom found that about 15% of Americans with constrictious conditions report pain regularly.
The number of Americans who experience pain regularly also increased from 2007 to 2015.